Posted 10th June 2019 by Joshua Broomfield
The combination of simplicity and power is turning flow cytometry into the highest throughput protein analysis method yet developed.
Large-scale protein analysis, or proteomics, is still a relatively small discipline where the research front is driven by a few labs with unrestricted access to mass spectrometry (MS). MS is equivalent to a mainframe computer: very big, very sophisticated, and only a few people have the skills to use them.
Posted 7th June 2019 by Joshua Broomfield
One of the frustrations I have with Flow Cytometry is when companies present their amazing new findings at conferences, and it’s quite often about TMB cells. In my case, I work on these cells perhaps 20% of the time. The rest of the time I work on cells from other parts of the human body – bone marrow, lung, bronchoalveolar lavage, spleen – and in diverse animals such as mice, rats, and even sparrow, chicken, and mosquito.
Posted 5th June 2019 by Joshua Broomfield
Denise Anderson is president of the Health Information Sharing and Analysis Centre (H-ISAC), USA. She spoke to us about her perspective on Healthcare Cybersecurity, the value of information sharing, and the paradigm shift the industry requires in light of new risks brought about by rapid innovation.
Posted 3rd June 2019 by Joshua Broomfield
There is a huge need to identify biomarkers to discern which metastatic colorectal cancer patients will benefit from treatment using Regorafenib. Despite being the latest approved drugs for the disease, Regorafenib has limited clinical efficacy and is associated with a number of side effects. However, a lot of patients are treated with Regorafenib as it is the only treatment available for patients who cannot receive anti-EGFR treatment due to K-RAS or BRAF mutation.
Posted 31st May 2019 by Joshua Broomfield
The ability to measure multiple forms of cell death simultaneously represents a significant development for such techniques. I have been using antibodies and more specific forms of dyes to identify mitochondrial activity and reactive oxygen in roughly fifty populations, whereas normally it would only be able to measure one at a time. I will be discussing this work at the Flow Cytometry Congress, and it could prove enormously beneficial to drug and immunotherapy development.
Posted 29th May 2019 by Joshua Broomfield
Manuela Maria Schöner, part of the Corporate Strategy & Consulting division at Boehringer Ingelheim, spoke to us recently about her work with blockchain. She described her perspective on the use of data in the industry, and how Blockchain could become a key tool in meeting the needs of the primary stakeholders: patients.
Posted 24th May 2019 by Joshua Broomfield
The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.
Posted 22nd May 2019 by Joshua Broomfield
In my previous post, I discussed the likely applications of Blockchain technology in the short, medium, and long-term future. These applications follow on from the key strategic priorities necessitated by the healthcare industry’s trend towards digital decentralized care delivery models.